Meilleure Health has cooperated with Vazyme to obtain the global agency of 2019-nCoV IgG/IgM Detection Kit
On April 11, 2020, the business division of Fighting Against the 2019-nCoV Group of Meilleure Health made important progress. Meilleure obtained the global agent sales right of Vazyme Biotech's 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold-Based), as well as the exclusive agency right in Switzerland, India and Africa, and formally signed the cooperation agreement.
Vazyme Biotech Co.,Ltd developed the highly sensitive and specific 2019-ncov IgG/IgM Detection Kit (Colloidal gold-based) by virtue of its strong R&D strength and officially passed the emergency approval of the National Medical Products Administration, becoming one of the eight antibody detection reagents approved by NMPA (as of March 31). The kit has the advantages of simple sampling, high detection efficiency and only requires 10 minutes to obtain the results. IgG/IgM Detection reagent is an important supplement to nucleic acid detection reagents, which can be used as a supplementary detection index of the 2019-nCoV nucleic acid test negative suspected cases or in cooperation with nucleic acid detection in the diagnosis of suspected cases. A combination of the two kits can quickly determine whether a patient has been infected with 2019-nCoV within 10 minutes. It has been certified by the Health Sciences Authority (HSA) of Singapore, the European Union CE permit, and three kinds of medical device licenses. It has helped prevent and control outbreaks in many countries with its professional strength.
Meilleure Health has been actively responding to the outbreak of the 2019-nCoV to support China's and global fight against the epidemic. At different stages of the epidemic development, Meilleure Health implemented different measures according to the current situation: during the initial outbreak stage, we donated several times to the first-line anti-epidemic units in key epidemic areas such as Hubei, Hunan, medical teams in Hubei, and the third hospitals in Shenzhen. Its cell plate company immediately signed an agreement with the only designated 2019-nCoV treatment hospital in Shenzhen to promote the clinical treatment of critically ill patients with stem cells. In the stage of resuming production, it has transformed into the production of masks, helping the government to guarantee the resources of epidemic prevention. With 22 production lines, it has reached the daily production capacity of 1 million masks. After the outbreak of 2019-nCoV in foreign countries one after another, it launched the business division of Fighting Against the 2019-nCoV Group, taking advantage of their own network at home and abroad to supply the world with key anti-epidemic materials such as novel coronavirus detection kits and masks. Previously, Meilleure became the global authorized partner of the leading nucleic acid kit enterprise Sansure Biotech Inc., and has offered help to many countries in Europe, Latin America and north Africa, as well as the world's second most populous country, India.
After this cooperation with Vazyme, Meilleure Health will continue to take advantage of its international layout to provide more countries and regions with necessary anti-epidemic medical supplies. Meilleure also hopes that with the efforts of all countries in the world, people in the world can overcome the once-in-a-century epidemic at an early date and return to normal life and work.
China's Powerhouses For Global Epidemic Control: Meilleure and Sansure Join Forces To Supply Overseas Anti-epidemic Resources
Company Name: Meilleure Health International Industry Group